HRMYHarmony Biosciences Holdings, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +16% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 10% since the previous count, unchanged over three months.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How HRMY is trading
Harmony Biosciences Holdings, Inc. is +24% over the past year while the S&P 500 is +18%: 5.6 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +16%
vs 200-day average · a clear uptrend
- RSI (14)
- 36
RSI (14) · neutral
- Below its 52-week high
- 6.0%
Below its 52-week high
Details›
- Last close2026-10-09
- $40.31
- 1 monthS&P 500 +2.7%
- −1.9%
- 1 yearS&P 500 +18%
- +24%
- 5 yearsS&P 500 +88%
- +13%
- vs 50-day average$39.86
- +1.1%
- 52-week high
- $42.88
- 52-week low
- $25.90
- Annualised volatility
- 45%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$3.1M
| Year | Return |
|---|---|
| 2026 (year to date) | +7.7% |
| 2025 | +8.7% |
| 2024 | +6.5% |
| 2023 | −41% |
| 2022 | +29% |
| 2021 | +18% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 1 of 6 | −3.6% |
| Feb | 6 | 2 of 6 | −5.2% |
| Mar | 6 | 2 of 6 | −1.7% |
| Apr | 6 | 1 of 6 | −4.6% |
| May | 6 | 4 of 6 | +4.4% |
| Jun | 6 | 4 of 6 | +0.70% |
| Jul | 6 | 5 of 6 | +4.2% |
| Aug | 6 | 5 of 6 | +6.7% |
| Sep | 7 | 3 of 7 | −2.1% |
| Oct | 7 | 5 of 7 | −0.15% |
| Nov | 6 | 5 of 6 | +11% |
| Dec | 6 | 3 of 6 | +2.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.